Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: Week 192 results from a phase IIb randomized trial

AIDS Research and Human Retroviruses

Volumn 28, Issue 5, 2012, Pages 437-446

  Wilkin, Aimee ^a   Pozniak, Anton L ^b   Morales Ramirez, Javier ^c   Lupo, Sergio H ^d   Santoscoy, Mario ^e   Grinsztejn, Beatriz ^f   Ruxrungtham, Kiat ^g   Rimsky, Laurence T ^h   Vanveggel, Simon ^h   Boven, Katia ⁱ  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c Clinical Research Puerto Rico Inc   (Puerto Rico)

^d UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f Funda??o Oswaldo Cruz   (Brazil)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h TIBOTEC BVBA   (Belgium)

ⁱ Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RILPIVIRINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOCALCEMIA; IMMUNE RESPONSE; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL; NIGHTMARE; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84860455337     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0050     Document Type: Article

References (18)

1. Killingley B and Pozniak A: The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today 2007;43:427-442. (Pubitemid 47344920)
2. FDA label for Sustiva (efavirenz) capsules and tablets. Bristol-Myers Squibb Company. 2010. Available at http:// packageinserts.bms.com/pi/pi-sustiva. pdf. Accessed February 3, 2011.
3. US DHHS: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 2011. Available at http://aidsinfo.nih.gov/contentfiles/Adultand AdolescentGL.pdf. Accessed February 3, 2011.
4. European AIDS Clinical Society: Guidelines for the clinical management and treatment of HIV-infected adults in Europe. April 2011. Available at http://www.europeanaids clinicalsociety.org/images/stories/EACS-Pdf/eacs- euroguide lines-fullversion.pdf. Accessed February 3, 2011.
5. Azijn H, Tirry I, Vingerhoets J, et al.: TMC278, a next-generation NNRTI, active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-727.
6. Katlama C, Haubrich R, Lalezari J, et al.: Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-2300.
7. FDA label for EDURANTTM (rilpivirine) tablets. 2011. www .accessdata.fda.gov/drugsatfda-docs/label/2011/202022s000lbl .pdf. Accessed May 28, 2011.
8. Molina JM, Cahn P, Grinsztejn B, et al, for the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind activecontrolled trial. Lancet 2011;378:238-246.
9. Cohen CJ, Andrade-Villanueva J, Clotet B, et al, for the THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-237.
10. FDA label for COMPLERAT- (emtricitabine/rilpivirine/ tenofovir disoproxil fumarate) tablets. 2011. Available at: http://www.gilead.com/pdf/complera-pi. pdf. Accessed September 12, 2011.
11. Pozniak AL, Morales-Ramirez J, Katabira E, et al.: Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a Phase IIb randomized trial. AIDS 2010; 24:55-65.
12. FDA Guidance for Industry: Antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval, prepared by the Division of Antiviral Drug Products: Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER), Appendix B. October 2002. Available at http:// www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070968.pdf. Accessed February 3, 2011.
13. Division of Acquired Immune Deficiency Syndrome (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 1. December 28, 2004. Available at http://www.niaid.nih.gov/LabsAndResources/resources/ DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. Accessed February 3, 2011.
14. Vanveggel S, Buelens A, Crauwels HM, et al.: TMC278 25mg qd has no effect on corrected QT interval in a study in HIVnegative volunteers. 12th European AIDS Conference; Cologne, Germany, November 2009 [abstract PE7.1/2].
15. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naïve patients: A 3-year randomized trial. JAMA 2004;292:191-201. (Pubitemid 38917996)
16. Arribas JR, Pozniak AL, Gallant JE, et al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-78. (Pubitemid 351619372)
17. Hill A and DeMasi R: Discordant conclusions from HIV efficacy trials-an evaluation of efficacy endpoints. Antivir Ther 2005;10:367-374. (Pubitemid 41151015)
18. Rimsky L, Vingerhoets J and Van Eygen V, et al.: Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients failing TMC278 in the phase 3 studies ECHO and THRIVE: 48-week analysis [Abstract 49]. Antivir Ther. 2011;16(Suppl 1):A17.